Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    22649106 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG)
Condition: Acute Myeloid Leukemia
Interventions: Drug: Cytarabine;   Drug: Thioguanine;   Drug: Daunorubicin;   Drug: Cyclophosphamide;   Drug: G-CSF;   Procedure: Autologous stem cell transplantation;   Procedure: Allogeneic stem cell transplantation
2 Active, not recruiting Evaluation of "Dose-dense Therapy" by S-HAM in Comparison to Conventionally Timed Double Induction in Patients With Acute Myeloid Leukemia (AML)
Condition: Acute Myeloid Leukemia
Intervention: Drug: Ara-C, Mitoxantrone, Daunorubicin, Thioguanin

Indicates status has not been verified in more than two years